JP2014503593A - 閉塞性睡眠時無呼吸を処置するための方法 - Google Patents
閉塞性睡眠時無呼吸を処置するための方法 Download PDFInfo
- Publication number
- JP2014503593A JP2014503593A JP2013551354A JP2013551354A JP2014503593A JP 2014503593 A JP2014503593 A JP 2014503593A JP 2013551354 A JP2013551354 A JP 2013551354A JP 2013551354 A JP2013551354 A JP 2013551354A JP 2014503593 A JP2014503593 A JP 2014503593A
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- osa
- subject
- apnea
- pyridostigmine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 59
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims abstract description 92
- 229960002290 pyridostigmine Drugs 0.000 claims abstract description 92
- 230000007958 sleep Effects 0.000 claims abstract description 79
- 206010041235 Snoring Diseases 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 208000008784 apnea Diseases 0.000 claims description 45
- 206010021079 Hypopnoea Diseases 0.000 claims description 42
- 210000002966 serum Anatomy 0.000 claims description 26
- 206010021143 Hypoxia Diseases 0.000 claims description 15
- 230000007954 hypoxia Effects 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 53
- 208000024891 symptom Diseases 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 description 25
- 206010041349 Somnolence Diseases 0.000 description 23
- 230000003860 sleep quality Effects 0.000 description 17
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 230000004622 sleep time Effects 0.000 description 13
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 12
- 206010062519 Poor quality sleep Diseases 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000002618 waking effect Effects 0.000 description 7
- 230000037007 arousal Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000863 loss of memory Toxicity 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 150000002926 oxygen Chemical class 0.000 description 5
- 208000002815 pulmonary hypertension Diseases 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000037321 sleepiness Effects 0.000 description 3
- 208000037905 systemic hypertension Diseases 0.000 description 3
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 cyclopyrrolone Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 0 CNC=CCCCOC(*=O)N(C)CC* Chemical compound CNC=CCCCOC(*=O)N(C)CC* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960002151 pyridostigmine bromide Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
- A61F5/56—Devices for preventing snoring
- A61F5/566—Intra-oral devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nursing (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437272P | 2011-01-28 | 2011-01-28 | |
| US61/437,272 | 2011-01-28 | ||
| PCT/US2012/022825 WO2012103398A2 (en) | 2011-01-28 | 2012-01-27 | Methods for treating obstructive sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000145A Division JP6342525B2 (ja) | 2011-01-28 | 2017-01-04 | 閉塞性睡眠時無呼吸を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503593A true JP2014503593A (ja) | 2014-02-13 |
| JP2014503593A5 JP2014503593A5 (enExample) | 2015-03-19 |
Family
ID=46577943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551354A Pending JP2014503593A (ja) | 2011-01-28 | 2012-01-27 | 閉塞性睡眠時無呼吸を処置するための方法 |
| JP2017000145A Active JP6342525B2 (ja) | 2011-01-28 | 2017-01-04 | 閉塞性睡眠時無呼吸を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000145A Active JP6342525B2 (ja) | 2011-01-28 | 2017-01-04 | 閉塞性睡眠時無呼吸を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8753327B2 (enExample) |
| EP (1) | EP2672972B1 (enExample) |
| JP (2) | JP2014503593A (enExample) |
| CN (2) | CN103458899A (enExample) |
| CA (1) | CA2825309C (enExample) |
| WO (1) | WO2012103398A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024143302A1 (ja) * | 2022-12-28 | 2024-07-04 | 西川株式会社 | 健康リスク判定システム、自律神経判定システム、生活改善システム、寝姿勢判定システム、寝姿勢判定プログラム、歯ぎしり検出システム、および歯ぎしり検出プログラム |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2672972B1 (en) * | 2011-01-28 | 2020-11-04 | Pfantastic Medical Research Institute, LLC | Methods for treating obstructive sleep apnea |
| EP3446663A1 (en) * | 2014-03-03 | 2019-02-27 | Sleep Innovations Pty Ltd | Device and method for sleep apnoea treatment |
| WO2016014229A1 (en) | 2014-07-25 | 2016-01-28 | Mendelowitz David | Oxytocin improves treatment of obstructive sleep apnea |
| AU2016243801B2 (en) | 2015-04-02 | 2020-05-21 | Hill-Rom Services Pte. Ltd. | Manifold for respiratory device |
| WO2018115351A1 (en) * | 2016-12-23 | 2018-06-28 | Koninklijke Philips N.V. | System for treating snoring among at least two users |
| GEP20227387B (en) * | 2017-04-28 | 2022-06-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| BR112020015316A2 (pt) | 2018-01-30 | 2020-12-08 | Apnimed, Inc. (Delaware) | Métodos e composições para o tratamento da apneia do sono |
| EP3824881B1 (en) * | 2018-06-18 | 2022-02-16 | Amneal Complex Products Research LLC | Extended release compositions comprising pyridostigmine |
| EP3840806B1 (en) * | 2018-08-24 | 2023-10-11 | Koninklijke Philips N.V. | Providing sleep therapy with a pressure therapy system |
| US20200281522A1 (en) | 2019-03-06 | 2020-09-10 | Medtronic Xomed, LLC | System and method for improved obstructive sleep apnea diagnostic for implantable devices |
| CN114504643B (zh) * | 2021-12-24 | 2024-03-26 | 北京大学第一医院 | 抗IgE抗体在用于治疗OSAS中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511873A (ja) * | 1995-12-19 | 2000-09-12 | エー プラス サイエンス インヴエスト アクチエボラグ | 睡眠時呼吸障害を治療および診断する方法、並びにこの方法を実施する手段 |
| JP2007502297A (ja) * | 2003-08-13 | 2007-02-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | コリンエステラーゼ阻害剤を用いる睡眠障害の処置 |
| WO2008042707A2 (en) * | 2006-09-29 | 2008-04-10 | Nellcor Puritan Bennett Llc | Device for managing obstructive sleep apnea and snoring |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2247662B (en) | 1990-08-31 | 1994-11-02 | Instance Ltd David J | Labels and manufacture thereof |
| CA2622721A1 (en) * | 2005-09-16 | 2007-03-22 | Cereuscience Ab | Method and means of preventing and treating sleep disordered breathing |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| EP2672972B1 (en) * | 2011-01-28 | 2020-11-04 | Pfantastic Medical Research Institute, LLC | Methods for treating obstructive sleep apnea |
-
2012
- 2012-01-27 EP EP12739245.4A patent/EP2672972B1/en active Active
- 2012-01-27 WO PCT/US2012/022825 patent/WO2012103398A2/en not_active Ceased
- 2012-01-27 CA CA2825309A patent/CA2825309C/en active Active
- 2012-01-27 JP JP2013551354A patent/JP2014503593A/ja active Pending
- 2012-01-27 US US13/359,692 patent/US8753327B2/en active Active
- 2012-01-27 CN CN2012800065522A patent/CN103458899A/zh active Pending
- 2012-01-27 CN CN201610821591.8A patent/CN107007602A/zh active Pending
-
2014
- 2014-05-05 US US14/269,326 patent/US9295670B2/en active Active
-
2017
- 2017-01-04 JP JP2017000145A patent/JP6342525B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511873A (ja) * | 1995-12-19 | 2000-09-12 | エー プラス サイエンス インヴエスト アクチエボラグ | 睡眠時呼吸障害を治療および診断する方法、並びにこの方法を実施する手段 |
| JP2007502297A (ja) * | 2003-08-13 | 2007-02-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | コリンエステラーゼ阻害剤を用いる睡眠障害の処置 |
| WO2008042707A2 (en) * | 2006-09-29 | 2008-04-10 | Nellcor Puritan Bennett Llc | Device for managing obstructive sleep apnea and snoring |
Non-Patent Citations (1)
| Title |
|---|
| JPN6016034591; ＮＥＷ薬理学（改訂第３版） , 19970801, ｐ．２３４-２４１ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024143302A1 (ja) * | 2022-12-28 | 2024-07-04 | 西川株式会社 | 健康リスク判定システム、自律神経判定システム、生活改善システム、寝姿勢判定システム、寝姿勢判定プログラム、歯ぎしり検出システム、および歯ぎしり検出プログラム |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2672972B1 (en) | 2020-11-04 |
| WO2012103398A2 (en) | 2012-08-02 |
| US20140238412A1 (en) | 2014-08-28 |
| CA2825309A1 (en) | 2012-08-02 |
| US8753327B2 (en) | 2014-06-17 |
| CN107007602A (zh) | 2017-08-04 |
| CN103458899A (zh) | 2013-12-18 |
| JP6342525B2 (ja) | 2018-06-13 |
| EP2672972A4 (en) | 2014-09-10 |
| WO2012103398A9 (en) | 2012-09-27 |
| CA2825309C (en) | 2019-10-01 |
| EP2672972A2 (en) | 2013-12-18 |
| US9295670B2 (en) | 2016-03-29 |
| JP2017095485A (ja) | 2017-06-01 |
| US20120197235A1 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6342525B2 (ja) | 閉塞性睡眠時無呼吸を処置するための方法 | |
| Hedner et al. | A randomized controlled clinical trial exploring safety and tolerability of sulthiame in sleep apnea | |
| Robinson et al. | Sleep· 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension | |
| Casey et al. | Sleep-related hypoventilation/hypoxemic syndromes | |
| Hla et al. | The effect of correction of sleep-disordered breathing on BP in untreated hypertension | |
| Farney et al. | Sleep-disordered breathing associated with long-term opioid therapy | |
| US5612379A (en) | Modafinil for the treatment of sleep apneas and ventilatory disorders of central origin | |
| CN110799181A (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
| JP5093967B2 (ja) | 睡眠時の自律的安定性に関するカンナビノイドの機能的役割 | |
| JP7705348B2 (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| Jyothi et al. | Obstructive sleep apnea: A pathophysiology and pharmacotherapy approach | |
| Carswell et al. | Obstructive sleep apnea: Part I. Pathophysiology, diagnosis, and medical management | |
| HK1241728A1 (en) | Methods for treating obstructive sleep apnea | |
| JP2019511555A (ja) | 睡眠時無呼吸の処置のためのスルチアム | |
| CN101641090B (zh) | 莫达非尼在制备治疗多动腿综合征的药物中的应用 | |
| Krieger et al. | Obstructive sleep apnea and cardiovascular disease: Implications for clinical practice | |
| Calianese et al. | Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea | |
| KR20250000641A (ko) | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 | |
| King | The Effect of Mandibular Advancement Devices on Sympathetic Nerve Activity and Markers of Cardiovascular Health in Obstructive Sleep Apnea Patients: A Feasibility Trial | |
| Dobbin et al. | Obstructive sleep apnea: recognition and management considerations for the aged patient | |
| Buchanan et al. | Continuous positive airway pressure | |
| Gorripati et al. | Pharmacological and Non-Pharmacological Management of Obstructive Sleep Apnea.(2023) | |
| Qamar et al. | Obstructive Sleep Apnea | |
| Colle et al. | Hypertension in Obstructive Sleep Apnoea | |
| Sleep | Sleep Stages |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150126 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160411 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160906 |